RxDoctor Payments Data

Won Seok Shin, MD

Family Medicine · Los Angeles, CANPI 1477015949

Payments from drug & device makers

$1,028in general payments, 2019–2025

Across 24 payments — averaging $42.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$245
  • Stryker$134
  • Viiv Healthcare Company$125
  • Pfizer$125
  • Regeneron Healthcare Solutions, Inc.$122
  • Merck$49
  • plus $228 from 9 others

What the payments were for

  • Food & beverage$1,028100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,028 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$63,785
Medicare patients
229
Services billed
552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$49,542
EliquisApixaban14$22,120
MounjaroTirzepatide13$12,686
Advair HfaFluticasone Propion/Salmeterol13$4,425
Wixela InhubFluticasone Propion/Salmeterol17$2,597
Atorvastatin Calcium229$1,964
Rosuvastatin Calcium84$1,784
Gabapentin81$1,579
PaxlovidNirmatrelvir/Ritonavir14$1,429
Losartan Potassium154$1,344
Amlodipine Besylate222$1,117
Levothyroxine Sodium65$822
Omeprazole68$704
Albuterol Sulfate HfaAlbuterol Sulfate34$692
Nifedipine ErNifedipine12$663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$245$49,54243 claims
PfizerEliquis, Paxlovid$125$23,54928 claims
Lilly USA, LLCMounjaro$25$12,68613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →